Bart Neyns - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber , Sandra P. D’Angelo , David R. Minor +25 more

2015 The Lancet Oncology 2617 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 8,278
Institution: Universitair Ziekenhuis Brussel

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-0658-5903

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.